Search Results - "Rini"

Product inspection policy for an imperfect production system with inspection errors and warranty cost: revisited by Rini

Get full text

Adjuvant therapy in renal cell carcinoma by Gul, Anita, Rini, Brian I.

“…Localized renal cell carcinoma (RCC) has an associated risk of recurrence after nephrectomy. Several clinical risk models attempt to predict oncologic outcomes…”
Get full text

Treatment of renal cell carcinoma: Current status and future directions by Barata, Pedro C., Rini, Brian I.

“…Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach…”
Get full text

COVID-19 and Cancer: Current Challenges and Perspectives by Bakouny, Ziad, Hawley, Jessica E., Choueiri, Toni K., Peters, Solange, Rini, Brian I., Warner, Jeremy L., Painter, Corrie A.

“…Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This effect has included the adverse outcomes in patients with cancer who…”
Get full text

Governing the ungovernable: The politics of disciplining pulpwood and palm oil plantations in Indonesia’s tropical peatland by Astuti, Rini

“…•The Indonesian Government failed in disciplining large-scale peatland users.•Major plantation companies steer their worker unions to resist peatland…”
Get full text

A REVIEW OF THE LITERATURE ON ZAKAH BETWEEN 2003 AND 2019 by Rini, Rini

“…This research aimed to critically review literature on the development of Zakah research from 2003 through 2019. This research employed a descriptive method…”
Get full text

Deepfakes and the Epistemic Backstop by Rini, Regina

“…Deepfake technology uses machine learning to fabricate video and audio recordings that represent actual people doing and saying things they've never done. In…”
Get full text

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages by Obradovic, Aleksandar, Chowdhury, Nivedita, Haake, Scott M., Ager, Casey, Wang, Vinson, Vlahos, Lukas, Guo, Xinzheng V., Aggen, David H., Rathmell, W. Kimryn, Jonasch, Eric, Johnson, Joyce E., Roth, Marc, Beckermann, Kathryn E., Rini, Brian I., McKiernan, James, Califano, Andrea, Drake, Charles G.

“…Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course. To assemble a comprehensive ccRCC tumor microenvironment…”
Get full text

Resistance to targeted therapy in renal-cell carcinoma by Rini, Brian I, Dr, Atkins, Michael B, Prof

“…Summary Therapeutic targeting of integral biological pathways, including those involving vascular endothelial growth factor (VEGF) and mammalian target of…”
Get full text

HIF Inhibitors: Status of Current Clinical Development by Fallah, Jaleh, Rini, Brian I.

“…Purpose of Review In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be…”
Get full text

The logic of challenging research into bias and social disparity by Rini, Regina

“…There are two problems with the logic of Cesario's argument for abandoning existing research on social bias. First, laboratory findings of decisional bias have…”
Get more information

Ushul al-Nahwi al-Arabi : Kajian Tentang Landasan Ilmu Nahwu by Rini, Rini

“…Nahwu is a very important science in learning Arabic because it contains Arabic rules and grammar. So far there are still many Arabic language learners who…”
Get full text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial by Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

“…The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive,…”
Get full text

Tasmim Ahdaf Ta'lim al-Muthala'ah al-Mu'tamadah 'Ala Tahlili al-Hajah Fi Syu'bah Ta'lim al-Lughah al-Arabiyah Bi Jami'ah Curup al-Islamiyah al-Hukumiyah by Rini, Rini

“…Students who choose to continue their studies in the IAIN Arabic education study program Curup face difficulties in learning Arabic. One of the difficulties…”
Get full text

Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43 by Dubé, Mathieu, Le Coupanec, Alain, Wong, Alan H M, Rini, James M, Desforges, Marc, Talbot, Pierre J

“…Human coronaviruses (HCoVs) are recognized respiratory pathogens for which accumulating evidence indicates that in vulnerable patients the infection can cause…”
Get full text

Social Systems and Individual Viewpoints:A Response to Critics by Rini, Regina

Get full text

The Ethics of Microaggression by Rini, Regina

Get full text

Fixing flammable Forest: The scalar politics of peatland governance and restoration in Indonesia by Astuti, Rini

“…Peatland fires and the impact of transboundary haze are often intertwined with socio‐environmental externalities of neoliberal forest governance and…”
Get full text

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 by Escudier, Bernard, Motzer, Robert J., Tannir, Nizar M., Porta, Camillo, Tomita, Yoshihiko, Maurer, Matthew A., McHenry, M. Brent, Rini, Brian I.

“…In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses,…”
Get full text

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial by Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J

“…PurposeTo report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab…”
Get full text